BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 18657100)

  • 1. Pfizer is asked to suspend sales of painkiller.
    Lenzer J
    BMJ; 2005 Apr; 330(7496):862. PubMed ID: 15831855
    [No Abstract]   [Full Text] [Related]  

  • 2. Should off-label drugs be included as comparators in pharmacoeconomic studies?
    Walton SM; Schumock GT
    Pharmacoeconomics; 2014 Nov; 32(11):1035-7. PubMed ID: 25270597
    [No Abstract]   [Full Text] [Related]  

  • 3. US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research.
    Neumann PJ; Lin PJ; Hughes TE
    Pharmacoeconomics; 2011 Aug; 29(8):687-92. PubMed ID: 21732704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDAMA 1997 Section 114: another look.
    Jackson J
    Value Health; 2009; 12(2):191-2. PubMed ID: 18657097
    [No Abstract]   [Full Text] [Related]  

  • 5. AMCP Seeks an End to 20 Years Of Confusion Over FDAMA Section 114.
    Dalzell MD
    Manag Care; 2016 Sep; 25(9):43-45. PubMed ID: 28121576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 7. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 9. What ever happened to FDAMA Section 114? A look back after 10 years.
    Neumann PJ
    Value Health; 2009; 12(2):189-90. PubMed ID: 18657100
    [No Abstract]   [Full Text] [Related]  

  • 10. FDAMA Section 114: Why the Renewed Interest?
    Perfetto EM; Burke L; Oehrlein EM; Gaballah M
    J Manag Care Spec Pharm; 2015 May; 21(5):368-74. PubMed ID: 25942998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.